This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to viral gastroenteritis (rotaviruses, noroviruses, caliciviruses, adenoviruses, sapoviruses, astroviruses). It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to Prion disease (CJD, vCJD). It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to rotaviruses. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to human coronaviruses (SARS-CoV, MERS-CoV and SARS-CoV-2. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to Toxoplasma gondii. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to HIV. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to rabies virus. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to HSV. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to human CMV. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter provides details of the viruses and other organisms that are more severe in immunocompromised patients (HIV, CMV, EBV, HSV, VZV, HHV6, HHV7, HHV8, adenoviruses, influenzaviruses, parainfluenzaviruses, RSV, SARS-CoV-2, HBV, HEV, polyomaviruses, papillomaviruses, parvovirus, T gondii). It gives details of symptoms, diagnosis, treatment and strategies for reducing the risk of severe symptoms.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to influenza viruses. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to parainfluenzaviruses. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to HAV. It provides information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to VZV. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to RSV. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter provides details of the different kinds of vaccines available (live, attenuated, killed, inactivated, recombinant, subunit, mRNA, DNA and vector) for virus infections (e.g. SARS-CoV-2, HAV, HBV, influenzaviruses, JEE, measlesvirus, mumpsvirus, rubellavirus, HPV, rabies, polio, rotavirus, smallpox, mpox, yellow fever virus) in humans. It details the routes of administration and usage (e.g. pre-exposure or post-exposure, childhood, occupational health, travel and for at-risk groups).

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to chlamydia (C.trachomatis, C.pneumoniae, C. psittaci, C. abortus, LGV). It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to HTLV. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to human papillomaviruses and polyomaviruses. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to measles virus. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.